Media Alert: Charmaine Returns To C-SPAN

C-SPAN Charmaine will be on C-SPAN tomorrow Saturday at 0800hrs, that would be 8:00 am, EST civilian time. Debating the Plan B political play and other news stories of the day.

We all are going with the Penta-Posse to watch from the green room. And eat all their donuts.

C-SPAN Washington Journal video here.

Tune in or TiVo and let us know what you think.

Check local listing here.

The press release from Barr,

Plan B should not be used as routine contraception and does not protect against HIV/AIDS and sexually transmitted diseases (STDs).

Was this helpful? Do comment.

Consider a free eMail subscription for this site.

Thank you (foot)notes:

Barr’s release, continues:

FDA Grants OTC Status to Barr’s Plan B(R) Emergency Contraceptive

Historic Dual Status Decision Provides OTC Access to Those 18 Years of Age and Older; Remains Prescription for Women 17 and Younger

WOODCLIFF LAKE, N.J., Aug. 24 /PRNewswire-FirstCall/ — Barr Pharmaceuticals, Inc. (NYSE: BRL) today said that the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Application (sNDA) filed by Barr’s wholly-owned subsidiary, Duramed Pharmaceuticals, Inc., to market the Plan B(R) (levonorgestrel) emergency contraceptive Over-The-Counter (OTC) without a prescription. In approving the sNDA, FDA granted OTC status for consumers 18 years of age and older, while maintaining the prescription status for women 17 and younger. The Company’s Plan B OTC product and the prescription product will be marketed as a single package, which will allow for a prescription label to be adhered to the package when dispensed to women age 17 and younger. Because Plan B will still remain a prescription product for women 17 and younger, it will be sold in retail pharmacy outlets from behind the counter. Duramed plans to introduce the dual status Rx/OTC version of the product before the end of the calendar year.

More on Barr Pharmaceuticals, Inc..